Pfizer Germany has launched an online campaign to raise awareness of the progressive connective tissue disorder Dupuytren's contracture.

Based around the dupuytren-loesen.de website it offers patients and their families information on the disorder, including a self-test checklist, patient stories and a series of questions to ask their doctor.

Pfizer's novel, first-in-class, biologic Xiapex (collagenase clostridium histolyticum) was approved in Europe last March to treat Dupuytren's contracture and launched in a number of European countries, including Germany, Spain and the UK, during 2011.

The pharma company said its new German online portal would help visitors to understand the disease and give them an over view of the treatment options, with and with surgery, that are available.

Dupuytren's contracture results in a patient's fingers bending towards the palm of their hand, traditionally requiring surgery to straighten them.

The condition most commonly occurs in white Europeans, affecting up to 20 per cent of men over 60 and up to 20 per cent of women over 80.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more